

Subject index

Volume 71 (2006)

Acyclic nucleotide analog; Tenofovir; Adefovir; Antiviral drug; Nucleotide; Prodrug; Intracellular **71**, 254

Acyclic nucleotide analogues; Adefovir; Cidofovir; Tenofovir; Open-ring ANP analogues **71**, 248

Acyclovir; Herpes simplex viruses; Antivirals; Ganciclovir; Tricyclic analogues; Fluorescence **71**, 134

Adefovir; Acyclic nucleotide analogues; Cidofovir; Tenofovir; Open-ring ANP analogues **71**, 248

Adefovir; Tenofovir; Antiviral drug; Nucleotide; Prodrug; Intracellular; Acyclic nucleotide analog **71**, 254

Adenovirus; Immunocompromised host; Antiviral; Cidofovir; Ribavirin; Immunotherapy **71**, 172

Aldehyde; Cowpox virus; Vaccinia virus; Pyran; Pyrazolone; Multicomponent reaction **71**, 201

Algorithm; HIV; Drug resistance; Interpretation system; Genotype; Phenotype **71**, 335

Alkoxyalkyl esters of cidofovir; CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154

Amantadine; Influenza; Neuraminidase; Oseltamivir; Zanamivir; Pathogenesis; Antiviral resistance **71**, 372

Animal model; Antiviral; Immunomodulator; Neuraminidase inhibitor **71**, 64

Animal model; Hepatitis C virus; Protease inhibitors; Polymerase inhibitors; HCV cell culture model **71**, 363

Animal model; Orthopoxvirus; Antiviral; IBT; Marboran **71**, 24

Animal models; Cytomegalovirus; Mouse; Rat; Guinea pig **71**, 164

Antagonist; CCR5; CXCR4; HIV; Chemokine receptor; gp120 Envelope **71**, 216

Antiretroviral drugs; HIV-1; Macrophages; CD4+ lymphocytes **71**, 293

Antisense oligonucleotides; Antiviral activity; HSV-1; HCMV; HIV-1 **71**, 307

Antiviral activity; Antisense oligonucleotides; HSV-1; HCMV; HIV-1 **71**, 307

Antiviral activity; Hepatitis B virus; Hepatitis B virus-s antigen; Hepatitis B virus-e antigen; Oxadiazoles **71**, 7

Antiviral; Adenovirus; Immunocompromised host; Cidofovir; Ribavirin; Immunotherapy **71**, 172

Antiviral agent; Nucleoside analogs; *cycloSal*-pronucleotides; Carbohydrate drugs **71**, 282

Antiviral agents; Pharmacology; Nucleoside analogs; HIV **71**, 322

Antiviral; Deoxyribozyme (DNAzyme); Respiratory syncytial virus; Nucleocapsid **71**, 31

Antiviral drug; Tenofovir; Adefovir; Nucleotide; Prodrug; Intracellular; Acyclic nucleotide analog **71**, 254

Antiviral drugs; Drug resistance; HIV; Influenza; Herpesviruses **71**, 117

Antiviral drugs; L-Nucleoside enantiomers **71**, 276

Antiviral; Immunomodulator; Animal model; Neuraminidase inhibitor **71**, 64

Antiviral nucleosides; HSV; EHV-1; FHV-1; Veterinary; Latency **71**, 127

Antiviral; Orthopoxvirus; Animal model; IBT; Marboran **71**, 24

Antiviral resistance; Influenza; Neuraminidase; Amantadine; Oseltamivir; Zanamivir; Pathogenesis **71**, 372

Antiviral therapy; Rhinovirus **71**, 391

Antivirals; Chronic hepatitis; HBV **71**, 206

Antivirals; Coronaviruses; SARS; Therapy **71**, 397

Antivirals; Herpes simplex viruses; Acyclovir; Ganciclovir; Tricyclic analogues; Fluorescence **71**, 134

Antivirals; Respiratory syncytial virus; Review **71**, 379

Antivirals; Three-dimensional culture models; Organotypic cultures **71**, 96

- BALB/C mouse**; SARS-CoV; Ribavirin; IMP dehydrogenase inhibitor; Enhancement; Infection; Severe acute respiratory syndrome; Coronavirus **71**, 53
- Bicyclic nucleoside analogue**; Varicella zoster virus; Shingles **71**, 149
- Carbohydrate drugs**; Nucleoside analogs; Antiviral agent; *cycloSal*-pronucleotides **71**, 282
- Carbohydrate-binding agents (CBA)**; Carbohydrate-binding proteins (CBP); Lectins; HIV; Virus entry; gp120 envelope **71**, 237
- Carbohydrate-binding proteins (CBP)**; Carbohydrate-binding agents (CBA); Lectins; HIV; Virus entry; gp120 envelope **71**, 237
- CCR5**; CXCR4; Antagonist; HIV; Chemokine receptor; gp120 Envelope **71**, 216
- CD4+ lymphocytes**; HIV-1; Macrophages; Antiretroviral drugs **71**, 293
- Cerebrospinal fluid**; Herpes simplex encephalitis; Polymerase chain reaction **71**, 141
- Cervical carcinoma**; Papillomavirus; Warts; Vaccines; Cidofovir **71**, 181
- Chemokine receptor**; CCR5; CXCR4; Antagonist; HIV; gp120 Envelope **71**, 216
- Chemotherapy**; HIV-1; Transcription; Tat; NF- κ B **71**, 301
- Chemotherapy**; NNRTI; Protease inhibitor; HIV; Drug development **71**, 77
- Chronic hepatitis**; HBV; Antivirals **71**, 206
- Cidofovir**; Acyclic nucleotide analogues; Adefovir; Tenofovir; Open-ring ANP analogues **71**, 248
- Cidofovir**; Adenovirus; Immunocompromised host; Antiviral; Ribavirin; Immunotherapy **71**, 172
- Cidofovir**; Papillomavirus; Cervical carcinoma; Warts; Vaccines **71**, 181
- CMV**; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154
- Complestatin**; Kistamicin; Vancomycin; Eremomycin; Hydrophobic derivatives; Viral entry **71**, 227
- Comutation**; HIV-1; Protease resistance mutations; Protease inhibitors; Treatment duration; Covariation **71**, 42
- Coronavirus**; SARS-CoV; Ribavirin; IMP dehydrogenase inhibitor; BALB/C mouse; Enhancement; Infection; Severe acute respiratory syndrome **71**, 53
- Coronaviruses**; SARS; Antivirals; Therapy **71**, 397
- Covariation**; HIV-1; Protease resistance mutations; Protease inhibitors; Treatment duration; Comutation **71**, 42
- Cowpox virus**; Vaccinia virus; Aldehyde; Pyran; Pyrazolone; Multicomponent reaction **71**, 201
- CXCR4**; CCR5; Antagonist; HIV; Chemokine receptor; gp120 Envelope **71**, 216
- Cyclohexenyl nucleoside**; HSV; HIV oligonucleotides; Polymerase; Reverse transcriptase; Hexitol nucleoside; Threosyl nucleosides **71**, 317
- cycloSal-pronucleotides**; Nucleoside analogs; Antiviral agent; Carbohydrate drugs **71**, 282
- Cytomegalovirus**; Animal models; Mouse; Rat; Guinea pig **71**, 164
- Deaminated TSAO**; TSAO compounds; Non-nucleoside HIV-1 RT inhibitors; Spironucleosides **71**, 15
- Delayed chain termination**; Herpes simplex virus; Kaposi's sarcoma-associated herpesvirus; Kinases; DNA polymerases; HIV reverse transcriptase **71**, 268
- Deoxyribozyme (DNAzyme)**; Respiratory syncytial virus; Antiviral; Nucleocapsid **71**, 31
- Development of allosteric polymerase inhibitors**; Rational design of an enzyme inhibitor and rational design of a drug; Types of polymerase inhibitors; Development of nucleoside analogs as polymerase inhibitors; Development of nucleotide analogs as polymerase inhibitors; Development of pyrophosphate analogs as polymerase inhibitors **71**, 90
- Development of nucleoside analogs as polymerase inhibitors**; Rational design of an enzyme inhibitor and rational design of a drug; Types of polymerase inhibitors; Development of nucleotide analogs as polymerase inhibitors; Development of pyrophosphate analogs as polymerase inhibitors; Development of allosteric polymerase inhibitors **71**, 90
- Development of nucleotide analogs as polymerase inhibitors**; Rational design of an enzyme inhibitor and rational design of a drug; Types of polymerase inhibitors; Development of nucleoside analogs as polymerase inhibitors; Development of pyrophosphate analogs as polymerase inhibitors; Development of allosteric polymerase inhibitors **71**, 90
- Development of pyrophosphate analogs as polymerase inhibitors**; Rational design of an enzyme inhibitor and rational design of a drug; Types of polymerase inhibitors; Development of nucleoside analogs as polymerase inhibitors; Development of nucleotide analogs as polymerase inhibitors; Development of allosteric polymerase inhibitors **71**, 90
- DNA polymerases**; Herpes simplex virus; Kaposi's sarcoma-associated herpesvirus; Kinases; HIV reverse transcriptase; Delayed chain termination **71**, 268
- Drug development**; Chemotherapy; NNRTI; Protease inhibitor; HIV **71**, 77
- Drug resistance**; Antiviral drugs; HIV; Influenza; Herpesviruses **71**, 117
- Drug resistance**; Hepatitis C virus (HCV); NS3 serine protease; NS5B RNA-dependent RNA polymerase; Target for antiviral therapy **71**, 351
- Drug resistance**; HIV; Interpretation system; Algorithm; Genotype; Phenotype **71**, 335
- EHV-1**; HSV; FHV-1; Veterinary; Antiviral nucleosides; Latency **71**, 127
- Enhancement**; SARS-CoV; Ribavirin; IMP dehydrogenase inhibitor; BALB/C mouse; Infection; Severe acute respiratory syndrome; Coronavirus **71**, 53
- Eremomycin**; Complestatin; Kistamicin; Vancomycin; Hydrophobic derivatives; Viral entry **71**, 227
- Evidence-based treatment**; Prophylaxis; Preemptive therapy; Herpesviruses **71**, 192
- FHV-1**; HSV; EHV-1; Veterinary; Antiviral nucleosides; Latency **71**, 127
- Fluorescence**; Herpes simplex viruses; Antivirals; Acyclovir; Ganciclovir; Tricyclic analogues **71**, 134

Fluorescence; MAb 2F5; HIV-1; Membrane **71**, 69

Foscarnet; CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir **71**, 154

Ganciclovir; CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154

Ganciclovir; Herpes simplex viruses; Antivirals; Acyclovir; Tricyclic analogues; Fluorescence **71**, 134

Genotype; HIV; Drug resistance; Interpretation system; Algorithm; Phenotype **71**, 335

gp120 envelope; Carbohydrate-binding agents (CBA); Carbohydrate-binding proteins (CBP); Lectins; HIV; Virus entry **71**, 237

gp120 Envelope; CCR5; CXCR4; Antagonist; HIV; Chemokine receptor **71**, 216

Guinea pig; Cytomegalovirus; Animal models; Mouse; Rat **71**, 164

HBV; Chronic hepatitis; Antivirals **71**, 206

HCMV; Antisense oligonucleotides; Antiviral activity; HSV-1; HIV-1 **71**, 307

HCV cell culture model; Hepatitis C virus; Protease inhibitors; Polymerase inhibitors; Animal model **71**, 363

Hepatitis B virus; Hepatitis B virus-s antigen; Hepatitis B virus-e antigen; Antiviral activity; Oxadiazoles **71**, 7

Hepatitis B virus-e antigen; Hepatitis B virus; Hepatitis B virus-s antigen; Antiviral activity; Oxadiazoles **71**, 7

Hepatitis B virus-s antigen; Hepatitis B virus; Hepatitis B virus-e antigen; Antiviral activity; Oxadiazoles **71**, 7

Hepatitis C virus (HCV); NS3 serine protease; NS5B RNA-dependent RNA polymerase; Target for antiviral therapy; Drug resistance **71**, 351

Hepatitis C virus; Protease inhibitors; Polymerase inhibitors; Animal model; HCV cell culture model **71**, 363

Herpes simplex encephalitis; Cerebrospinal fluid; Polymerase chain reaction **71**, 141

Herpes simplex virus; Kaposi's sarcoma-associated herpesvirus; Kinases; DNA polymerases; HIV reverse transcriptase; Delayed chain termination **71**, 268

Herpes simplex viruses; Antivirals; Acyclovir; Ganciclovir; Tricyclic analogues; Fluorescence **71**, 134

Herpesviruses; Antiviral drugs; Drug resistance; HIV; Influenza **71**, 117

Herpesviruses; Orthopoxviruses; Thymidine **71**, 1

Herpesviruses; Prophylaxis; Preemptive therapy; Evidence-based treatment **71**, 192

Heterocyclic thiosemicarbazones; Ribonucleotide reductases (RNRs); Oligopeptide/peptoid binding to RNR-R2 C-terminal sequences **71**, 122

Hexitol nucleoside; HSV; HIV oligonucleotides; Polymerase; Reverse transcriptase; Cyclohexenyl nucleoside; Threosyl nucleosides **71**, 317

HIV; Antiviral agents; Pharmacology; Nucleoside analogs **71**, 322

HIV; Antiviral drugs; Drug resistance; Influenza; Herpesviruses **71**, 117

HIV; Carbohydrate-binding agents (CBA); Carbohydrate-binding proteins (CBP); Lectins; Virus entry; gp120 envelope **71**, 237

HIV; CCR5; CXCR4; Antagonist; Chemokine receptor; gp120 Envelope **71**, 216

HIV; Chemotherapy; NNRTI; Protease inhibitor; Drug development **71**, 77

HIV; Drug resistance; Interpretation system; Algorithm; Genotype; Phenotype **71**, 335

HIV drug resistance; Microbicides; NNRTIs; NRTIs **71**, 343

HIV oligonucleotides; HSV; Polymerase; Reverse transcriptase; Hexitol nucleoside; Cyclohexenyl nucleoside; Threosyl nucleosides **71**, 317

HIV reverse transcriptase; Herpes simplex virus; Kaposi's sarcoma-associated herpesvirus; Kinases; DNA polymerases; Delayed chain termination **71**, 268

HIV-1; Antisense oligonucleotides; Antiviral activity; HSV-1; HCMV **71**, 307

HIV-1; Chemotherapy; Transcription; Tat; NF- κ B **71**, 301

HIV-1; MAb 2F5; Membrane; Fluorescence **71**, 69

HIV-1; Macrophages; CD4+ lymphocytes; Antiretroviral drugs **71**, 293

HIV-1; Protease resistance mutations; Protease inhibitors; Treatment duration; Covariation; Comutation **71**, 42

HIV-1; Reverse transcriptase; Integrase; Protease **71**, 260

HSV; EHV-1; FHV-1; Veterinary; Antiviral nucleosides; Latency **71**, 127

HSV; HIV oligonucleotides; Polymerase; Reverse transcriptase; Hexitol nucleoside; Cyclohexenyl nucleoside; Threosyl nucleosides **71**, 317

HSV-1; Antisense oligonucleotides; Antiviral activity; HCMV; HIV-1 **71**, 307

Hydrophobic derivatives; Complestatin; Kistamicin; Vancomycin; Eremomycin; Viral entry **71**, 227

IBT; Orthopoxvirus; Antiviral; Animal model; Marboran **71**, 24

Immunocompromised host; Adenovirus; Antiviral; Cidofovir; Ribavirin; Immunotherapy **71**, 172

Immunomodulator; Antiviral; Animal model; Neuraminidase inhibitor **71**, 64

Immunotherapy; Adenovirus; Immunocompromised host; Antiviral; Cidofovir; Ribavirin **71**, 172

IMP dehydrogenase inhibitor; SARS-CoV; Ribavirin; BALB/C mouse; Enhancement; Infection; Severe acute respiratory syndrome; Coronavirus **71**, 53

- Infection;** SARS-CoV; Ribavirin; IMP dehydrogenase inhibitor; BALB/C mouse; Enhancement; Severe acute respiratory syndrome; Coronavirus **71**, 53
- Inflammation;** Interferon **71**, 108
- Influenza;** Antiviral drugs; Drug resistance; HIV; Herpesviruses **71**, 117
- Influenza;** Neuraminidase; Amantadine; Oseltamivir; Zanamivir; Pathogenesis; Antiviral resistance **71**, 372
- Integrase;** HIV-1; Reverse transcriptase; Protease **71**, 260
- Interferon;** Inflammation **71**, 108
- Interpretation system;** HIV; Drug resistance; Algorithm; Genotype; Phenotype **71**, 335
- Intracellular;** Tenofovir; Adefovir; Antiviral drug; Nucleotide; Prodrug; Acyclic nucleotide analog **71**, 254
- Kaposi's sarcoma-associated herpesvirus;** Herpes simplex virus; Kinases; DNA polymerases; HIV reverse transcriptase; Delayed chain termination **71**, 268
- Kinases;** Herpes simplex virus; Kaposi's sarcoma-associated herpesvirus; DNA polymerases; HIV reverse transcriptase; Delayed chain termination **71**, 268
- Kistamicin;** Complestatin; Vancomycin; Eremomycin; Hydrophobic derivatives; Viral entry **71**, 227
- Latency;** HSV; EHV-1; FHV-1; Veterinary; Antiviral nucleosides **71**, 127
- Lectins;** Carbohydrate-binding agents (CBA); Carbohydrate-binding proteins (CBP); HIV; Virus entry; gp120 envelope **71**, 237
- MAb 2F5;** HIV-1; Membrane; Fluorescence **71**, 69
- Macrophages;** HIV-1; CD4+ lymphocytes; Antiretroviral drugs **71**, 293
- Marboran;** Orthopoxvirus; Antiviral; Animal model; IBT **71**, 24
- Membrane;** MAb 2F5; HIV-1; Fluorescence **71**, 69
- Microbicides;** HIV drug resistance; NNRTIs; NRTIs **71**, 343
- Mouse;** Cytomegalovirus; Animal models; Rat; Guinea pig **71**, 164
- Multicomponent reaction;** Cowpox virus; Vaccinia virus; Aldehyde; Pyran; Pyrazolone **71**, 201
- Neuraminidase;** Influenza; Amantadine; Oseltamivir; Zanamivir; Pathogenesis; Antiviral resistance **71**, 372
- Neuraminidase inhibitor;** Antiviral; Immunomodulator; Animal model **71**, 64
- NF- κ B;** HIV-1; Chemotherapy; Transcription; Tat **71**, 301
- NNRTI;** Chemotherapy; Protease inhibitor; HIV; Drug development **71**, 77
- NNRTIs;** HIV drug resistance; Microbicides; NRTIs **71**, 343
- Non-nucleoside HIV-1 RT inhibitors;** Deaminated TSAO; TSAO compounds; Spironucleosides **71**, 15
- Novel benzimidazole riboside antiviral drugs;** CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154
- NRTIs;** HIV drug resistance; Microbicides; NNRTIs **71**, 343
- NS3 serine protease;** Hepatitis C virus (HCV); NS5B RNA-dependent RNA polymerase; Target for antiviral therapy; Drug resistance **71**, 351
- NS5B RNA-dependent RNA polymerase;** Hepatitis C virus (HCV); NS3 serine protease; Target for antiviral therapy; Drug resistance **71**, 351
- Nucleocapsid;** Deoxyribozyme (DNAzyme); Respiratory syncytial virus; Antiviral **71**, 31
- Nucleoside analog;** CMV; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154
- Nucleoside analogs;** Antiviral agent; *cyclo*Sal-pronucleotides; Carbohydrate drugs **71**, 282
- Nucleoside analogs;** Antiviral agents; Pharmacology; HIV **71**, 322
- L-Nucleoside enantiomers;** Antiviral drugs **71**, 276
- Nucleotide analog;** CMV; Nucleoside analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154
- Nucleotide;** Tenofovir; Adefovir; Antiviral drug; Prodrug; Intracellular; Acyclic nucleotide analog **71**, 254
- Oligopeptide/peptoid binding to RNR-R2 C-terminal sequences;** Ribonucleotide reductases (RNRs); Heterocyclic thiosemicarbazones **71**, 122
- Open-ring ANP analogues;** Acyclic nucleotide analogues; Adefovir; Cidofovir; Tenofovir **71**, 248
- Organotypic cultures;** Three-dimensional culture models; Antivirals **71**, 96
- Orthopoxvirus;** Antiviral; Animal model; IBT; Marboran **71**, 24
- Orthopoxviruses;** Herpesviruses; Thymidine **71**, 1
- Oseltamivir;** Influenza; Neuraminidase; Amantadine; Zanamivir; Pathogenesis; Antiviral resistance **71**, 372
- Oxadiazoles;** Hepatitis B virus; Hepatitis B virus-s antigen; Hepatitis B virus-e antigen; Antiviral activity **71**, 7
- Papillomavirus;** Cervical carcinoma; Warts; Vaccines; Cidofovir **71**, 181
- Pathogenesis;** Influenza; Neuraminidase; Amantadine; Oseltamivir; Zanamivir; Antiviral resistance **71**, 372
- Pharmacology;** Antiviral agents; Nucleoside analogs; HIV **71**, 322
- Phenotype;** HIV; Drug resistance; Interpretation system; Algorithm; Genotype **71**, 335
- Polymerase chain reaction;** Herpes simplex encephalitis; Cerebrospinal fluid **71**, 141
- Polymerase;** HSV; HIV oligonucleotides; Reverse transcriptase; Hexitol nucleoside; Cyclohexenyl nucleoside; Threosyl nucleosides **71**, 317

- Polymerase inhibitors;** Hepatitis C virus; Protease inhibitors; Animal model; HCV cell culture model **71**, 363
- Preemptive therapy;** Prophylaxis; Herpesviruses; Evidence-based treatment **71**, 192
- Prodrug;** Tenofovir; Adefovir; Antiviral drug; Nucleotide; Intracellular; Acyclic nucleotide analog **71**, 254
- Prophylaxis;** Preemptive therapy; Herpesviruses; Evidence-based treatment **71**, 192
- Protease;** HIV-1; Reverse transcriptase; Integrase **71**, 260
- Protease inhibitor;** Chemotherapy; NNRTI; HIV; Drug development **71**, 77
- Protease inhibitors;** Hepatitis C virus; Polymerase inhibitors; Animal model; HCV cell culture model **71**, 363
- Protease inhibitors;** HIV-1; Protease resistance mutations; Treatment duration; Covariation; Comutation **71**, 42
- Protease resistance mutations;** HIV-1; Protease inhibitors; Treatment duration; Covariation; Comutation **71**, 42
- Pyran;** Cowpox virus; Vaccinia virus; Aldehyde; Pyrazolone; Multicomponent reaction **71**, 201
- Pyrazolone;** Cowpox virus; Vaccinia virus; Aldehyde; Pyran; Multicomponent reaction **71**, 201
- Pyrophosphate analog;** CMV; Nucleoside analog; Nucleotide analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Valaciclovir; Foscarnet **71**, 154
- Rat;** Cytomegalovirus; Animal models; Mouse; Guinea pig **71**, 164
- Rational design of an enzyme inhibitor and rational design of a drug;** Types of polymerase inhibitors; Development of nucleoside analogs as polymerase inhibitors; Development of nucleotide analogs as polymerase inhibitors; Development of pyrophosphate analogs as polymerase inhibitors; Development of allosteric polymerase inhibitors **71**, 90
- Respiratory syncytial virus;** Antivirals; Review **71**, 379
- Respiratory syncytial virus;** Deoxyribozyme (DNAzyme); Antiviral; Nucleocapsid **71**, 11
- Reverse transcriptase;** HIV-1; Integrase; Protease **71**, 260
- Reverse transcriptase;** HSV; HIV oligonucleotides; Polymerase; Hexitol nucleoside; Cyclohexenyl nucleoside; Threosyl nucleosides **71**, 317
- Review;** Respiratory syncytial virus; Antivirals **71**, 379
- Rhinovirus;** Antiviral therapy **71**, 391
- Ribavirin;** Adenovirus; Immunocompromised host; Antiviral; Cidofovir; Immunotherapy **71**, 172
- Ribavirin;** SARS-CoV; IMP dehydrogenase inhibitor; BALB/C mouse; Enhancement; Infection; Severe acute respiratory syndrome; Coronavirus **71**, 53
- Ribonucleotide reductases (RNRs);** Heterocyclic thiosemicarbazones; Oligopeptide/peptoid binding to RNR-R2 C-terminal sequences **71**, 122
- SARS;** Coronaviruses; Antivirals; Therapy **71**, 397
- SARS-CoV;** Ribavirin; IMP dehydrogenase inhibitor; BALB/C mouse; Enhancement; Infection; Severe acute respiratory syndrome; Coronavirus **71**, 53
- Severe acute respiratory syndrome;** SARS-CoV; Ribavirin; IMP dehydrogenase inhibitor; BALB/C mouse; Enhancement; Infection; Coronavirus **71**, 53
- Shingles;** Varicella zoster virus; Bicyclic nucleoside analogue **71**, 149
- Spironucleosides;** Deaminated TSAO; TSAO compounds; Non-nucleoside HIV-1 RT inhibitors **71**, 15
- Target for antiviral therapy;** Hepatitis C virus (HCV); NS3 serine protease; NS5B RNA-dependent RNA polymerase; Drug resistance **71**, 351
- Tat;** HIV-1; Chemotherapy; Transcription; NF- κ B **71**, 301
- Tenofovir;** Acyclic nucleotide analogues; Adefovir; Cidofovir; Open-ring ANP analogues **71**, 248
- Tenofovir;** Adefovir; Antiviral drug; Nucleotide; Prodrug; Intracellular; Acyclic nucleotide analog **71**, 254
- Therapy;** Coronaviruses; SARS; Antivirals **71**, 397
- Three-dimensional culture models;** Organotypic cultures; Antivirals **71**, 96
- Threosyl nucleosides;** HSV; HIV oligonucleotides; Polymerase; Reverse transcriptase; Hexitol nucleoside; Cyclohexenyl nucleoside **71**, 317
- Thymidine;** Orthopoxviruses; Herpesviruses **71**, 1
- Transcription;** HIV-1; Chemotherapy; Tat; NF- κ B **71**, 301
- Treatment duration;** HIV-1; Protease resistance mutations; Protease inhibitors; Covariation; Comutation **71**, 42
- Tricyclic analogues;** Herpes simplex viruses; Antivirals; Acyclovir; Ganciclovir; Fluorescence **71**, 134
- TSAO compounds;** Deaminated TSAO; Non-nucleoside HIV-1 RT inhibitors; Spironucleosides **71**, 15
- Types of polymerase inhibitors;** Rational design of an enzyme inhibitor and rational design of a drug; Development of nucleoside analogs as polymerase inhibitors; Development of nucleotide analogs as polymerase inhibitors; Development of pyrophosphate analogs as polymerase inhibitors; Development of allosteric polymerase inhibitors **71**, 90
- Vaccines;** Papillomavirus; Cervical carcinoma; Warts; Cidofovir **71**, 181
- Vaccinia virus;** Cowpox virus; Aldehyde; Pyran; Pyrazolone; Multicomponent reaction **71**, 201
- Valaciclovir;** CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valganciclovir; Foscarnet **71**, 154
- Valganciclovir;** CMV; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Novel benzimidazole riboside antiviral drugs; Alkoxyalkyl esters of cidofovir; Ganciclovir; Valaciclovir; Foscarnet **71**, 154
- Vancomycin;** Complestatin; Kistamicin; Eremomycin; Hydrophobic derivatives; Viral entry **71**, 227
- Varicella zoster virus;** Bicyclic nucleoside analogue; Shingles **71**, 149
- Veterinary;** HSV; EHV-1; FHV-1; Antiviral nucleosides; Latency **71**, 127

- Viral entry**; Complestatin; Kistamicin; Vancomycin; Eremomycin; Hydrophobic derivatives **71**, 227
- Virus entry**; Carbohydrate-binding agents (CBA); Carbohydrate-binding proteins (CBP); Lectins; HIV; gp120 envelope **71**, 237
- Warts**; Papillomavirus; Cervical carcinoma; Vaccines; Cidofovir **71**, 181
- Zanamivir**; Influenza; Neuraminidase; Amantadine; Oseltamivir; Pathogenesis; Antiviral resistance **71**, 372